Flovent Diskus News Today

Three of the four major inhaler manufacturers have announced plans to cap patient copays for all their inhalers at $35 a month in recent weeks, in addition to lowering the list prices of some of those products.

Three of the four major inhaler manufacturers have announced plans to cap patient copays for all their inhalers at $35 a month in recent weeks, in addition to lowering the list prices of some of those products.

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Three of the largest inhaler manufacturers have already said theyd be capping inhaler co-pays at $35 monthly.

Flovent, a common asthma medication, is no longer available in the U.S. Find out why that is, how you might be impacted, and what you can do.

With the discontinuation of Flovent, we must prevent gaps in care

New year, new changes to your prescriptions. At least thats the case for many patients diagnosed with asthma.

Drug manufacturer GSK has discontinued Flovent asthma inhaler in favor of generics. The move could lead to some logistical headaches at the pharmacy, experts say.

Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts shared comment.

Alternatives for young kids not readily available